NovoNordisk, LT dirt cheap | GLP-1 a misunderstood growth marketNOVO NORDISK B A/SOMXCOP_DLY:NOVO_BjornwaterlanderNovo Nordisk stock has lost quite some weight since the release of Eli lilly's drug Zepbound and Mounjaro and since the rise of compounded, or generic copycat GLP-1 alternatives. The growth of the company has slown down a bit, but the overall GLP-1 market growth is still impressive and misunderstood. Both Lilly and NVO have become some of the cheapest PEG stocks in the markets and compettitors, of which most known, Hims en hers health also took a slice of growth of this market by telehealth GLP-1 descriptions. The copycat descriptions could be dangerous due to unvalidated low quality GLP-1 or agonist GLP-1 substances. Therefore a lot of law suits have been initiated by NVO. Where Oral Wegovy still has to be FDA approved withinin ~4, 7 months in USA, the company also has new medication approvals awaiting in the pipeline, medications like Cagrisema. (Phase 3 clinical trials, approval in late 2025 or early 2026) Amycretin - a unimolecular long-acting GLP-1 and amylin receptor agonist. Where investors have already praised Lilly for the better drug, GLP-1 demand is surging harder than production for both companies. Where Wegovy and Ozempic are approved by The FDA to sell, many costs for the patients themselfs aren't covered by the health insurance yet. Wegovy or Zepbound isn't covered for mainstream when prescribed by your physician yet. it's only covered for severe obisty for example. Therefore penetration rates of the drug aren't very high yet and will get higher where it will be coverd for more people. Also due to the high cost many copycat GLP-1 agonist market have arisen. There is some improvement in cost coverage for these types of medicine Which will boost the revenue due to prescribtion sales. Next these facts, there are still new markets for GLP-1 to be approved like in india and Japan where worldwide demand is much greather than production capacity. Both Lilly and NVO are expanding fast. Many new production volume is created and Needed!, NVO is expanding production sites in brazil and china. I'm exited for the earnings today. NVO has had many dumps before but has proven to be a up only company. The profits of the company have doubled from $7B to >$14B since Wegovy FDA approval. from the top shares have dumped 70% where there is still >10% growth. Since the FDA approval (june 2021), other markets excluded the share is just +40% up. The stock is much cheaper now with double the profits and revenue, and still >10% growth. Let's see what happens with earnings. Good luck.